Full Press Release Details
Cellectar Biosciences to Present at the
10th Annual LD Micro Main Event
Wisc., (November 20, 2017) -- Cellectar Biosciences (Nasdaq: CLRB), a clinical stage
biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today
announced that it will be presenting at the 10th Annual LD Micro Main Event on Tuesday, December 5th
at 8:30 AM PT/11:30 AM ET. Jim Caruso, president and CEO of Cellectar, will present the company and meet with investors.
The company's presentation will also be webcast at http://wsw.com/webcast/ldmicro13/clrb/,
and will be posted on the company's website following the conference. The LD Micro Main Event will be held at the Luxe
Sunset Bel Air Hotel in Los Angeles.
About Cellectar Biosciences, Inc.
Cellectar Biosciences (Nasdaq: CLRB) is developing phospholipid drug conjugates (PDCs) designed to provide cancer targeted delivery
of diverse oncologic payloads to a broad range of cancers and cancer stem cells. Cellectar's PDC platform is based on the company's
proprietary phospholipid ether analogs. These novel small-molecules have demonstrated highly selective uptake and retention in
a broad range of cancers, even sites of metastases. The company's lead therapeutic PDC, CLR 131, utilizes iodine-131, a cytotoxic
radioisotope, as its payload. CLR 131 has been designated as an orphan drug by the US FDA and is currently being evaluated in a
Phase 1 clinical study in patients with relapsed or refractory multiple myeloma and a Phase 2 clinical study to assess efficacy
in a range of B-cell malignancies. The company is also developing proprietary PDCs for targeted delivery of chemotherapeutics and
has several preclinical stage product candidates, and plans to expand its PDC chemotherapeutic pipeline through both in-house and
collaborative R&D efforts. For more information please visit www.cellectar.com.
LD Micro was founded in 2006 with the sole purpose of being
an independent resource in the microcap space. What started out as a newsletter highlighting unique companies has transformed into
an event platform hosting several influential conferences annually (Invitational, Summit, and Main Event).
In 2015, LDM launched the first pure microcap index (the LDMi)
to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of
everyone in the small and microcap universe.
This news release contains forward-looking statements.
You can identify these statements by our use of words such as "may," "expect," "believe," "anticipate,"
"intend," "could," "estimate," "continue," "plans," or their negatives or cognates.
These statements are only estimates and predictions and are subject to known and unknown risks and uncertainties that may cause
actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs
and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause
such a material difference include, among others, uncertainties related to the ability to raise additional capital, uncertainties
related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful
preclinical development thereof, the completion of clinical trials, the FDA review process and other government regulation, our
pharmaceutical collaborators' ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical
companies, product pricing and third-party reimbursement. A complete description of risks and uncertainties related to our business
is contained in our periodic reports filed with the Securities and Exchange Commission including our Form 10-K for the year ended
December 31, 2016. These forward-looking statements are made only as of the date hereof, and we disclaim any obligation to
update any such forward-looking statements.